BACKGROUND: Patients with brain tumour usually suffer from increased pressure in the skull due to swelling of brain tissue. A swollen brain renders surgical removal of the brain tumour difficult. To ease surgical tumour removal, measures are taken to reduce brain swelling, often referred to as brain relaxation. Brain relaxation can be achieved with intravenous fluids such as mannitol or hypertonic saline. This review was conducted to find out which of the two fluids may have a greater impact on brain relaxation.
hypertonic saline group was 0.60 (95% confidence interval (CI) 0.44 to 0.83, low-quality evidence). One trial reported ICU and hospital stay. The mean (standard deviation (SD)) duration of ICU stay in the mannitol and hypertonic saline groups was 1.28 (0.5) and 1.25 (0.5) days (P value 0.64), respectively; the mean (SD) duration of hospital stay in the mannitol and hypertonic saline groups was 5.7 (0.7) and 5.7 (0.8) days (P value 1.00), respectively. AUTHORS' CONCLUSIONS: From the limited data available on the use of mannitol and hypertonic saline for brain relaxation during craniotomy, it is suggested that hypertonic saline significantly reduces the risk of tense brain during craniotomy. A single trial suggests that ICU stay and hospital stay are comparable with the use of mannitol or hypertonic saline. However, focus on other related important issues such as long-term mortality, long-term outcome, adverse events and quality of life is needed. 
COMMENTS
Hyperosmolar therapy, using mannitol or hypertonic saline solution, is the main medical management method for providing brain relaxation during neurosurgical procedures in which craniotomy and opening of the dura mater are performed, especially in patients with intracranial hypertension. When the blood-brain barrier (BBB) is intact, an increase in serum osmolality produces brain dehydration, thereby reducing the cerebral volume as well as the intracranial pressure. The hydroelectrolytic changes caused by hyperosmolar therapy are a confounding factor in managing neurosurgical patients, who frequently have hydroelectrolytic imbalances, usually attributed to salt wasting syndrome, inadequate antidiuretic hormone secretion and diabetes insipidus. Although mannitol has been used since the 1980s and remains the first choice in many circumstances, use of hypertonic saline solution is becoming much greater, which explains why several studies have compared these two therapies during neurosurgical procedures in which craniotomy is required. In this manuscript, the authors conducted a systematic review that brought together six randomized controlled trials comparing the use of mannitol versus hypertonic saline for brain relaxation. The primary outcomes were mortality, long-term follow-up, Glasgow Outcome Scale score at three months and any adverse events relating to mannitol or hypertonic saline solution, but none of these were mentioned in the studies included. Regarding the secondary outcomes, brain relaxation was better achieved in the hypertonic saline group, since brain relaxation in the mannitol group was considered inadequate in 35.8% of the cases, versus 21.3% in the hypertonic saline group. Hospital and inten-sive care unit stay were not significantly different between the groups. Lastly, further studies are required in order to clarify the risks and benefits of these two therapies in specific situations such as brain tumor surgery, traumatic brain injury and aneurysmal subarachnoid hemorrhage, for instance.
